These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 90214)

  • 21. The acceptability, safety, and tolerability of methadone/naloxone in a 50:1 ratio.
    Bell J; Shearer J; Ryan A; Graham R; Korompay K; Rizzo S; Sindhusake D; Somogyi AA
    Exp Clin Psychopharmacol; 2009 Jun; 17(3):146-53. PubMed ID: 19586229
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Buprenorphine: an alternative to methadone for heroin dependence treatment.
    Resnick RB; Galanter M; Pycha C; Cohen A; Grandison P; Flood N
    Psychopharmacol Bull; 1992; 28(1):109-13. PubMed ID: 1609035
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Retention of patients in the New York City methadone maintenance treatment program.
    Newman RG; Tytun A; Bashkow S
    Int J Addict; 1976; 11(5):905-31. PubMed ID: 1017914
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The prognosis of patients detoxified from methadone maintenance: a follow-up study.
    Stimmel B; Rabin J; Engel C
    Proc Natl Conf Methadone Treat; 1973; 1():270-4. PubMed ID: 4808158
    [No Abstract]   [Full Text] [Related]  

  • 25. A follow-up study of dropouts from a methadone maintenance program.
    Boudouris J
    Int J Addict; 1976; 11(5):807-30. PubMed ID: 1017909
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An epidemiologic evaluation of long-term methadone maintenance treatment for heroin addiction.
    Gearing FR; Schweitzer MD
    Am J Epidemiol; 1974 Aug; 100(2):101-12. PubMed ID: 4850534
    [No Abstract]   [Full Text] [Related]  

  • 27. Psychoeducational group approach: HIV risk reduction in drug users.
    Sorensen JL; London J; Heitzmann C; Gibson DR; Morales ES; Dumontet R; Acree M
    AIDS Educ Prev; 1994 Apr; 6(2):95-112. PubMed ID: 8018443
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Short-term detoxification with methadone.
    Senay EC; Dorus W; Showalter CV
    Ann N Y Acad Sci; 1981; 362():203-16. PubMed ID: 7020530
    [No Abstract]   [Full Text] [Related]  

  • 29. Supervised injectable heroin or injectable methadone versus optimised oral methadone as treatment for chronic heroin addicts in England after persistent failure in orthodox treatment (RIOTT): a randomised trial.
    Strang J; Metrebian N; Lintzeris N; Potts L; Carnwath T; Mayet S; Williams H; Zador D; Evers R; Groshkova T; Charles V; Martin A; Forzisi L
    Lancet; 2010 May; 375(9729):1885-95. PubMed ID: 20511018
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Feasibility of double-blind clinical trials with oral diacetylmorphine: a randomized controlled phase II study in an inpatient setting.
    Colom Farran J; Casas M; Pérez de Los Cobos J; Del Río M; Roncero C; Castells X; Valero S; Eiroa-Orosa FJ; Batlle F; Trujols J
    Eur Addict Res; 2012; 18(6):279-87. PubMed ID: 22854605
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Choice of blind methadone dose increases by methadone maintenance patients.
    Bickel WK; Higgins ST; Stitzer ML
    Drug Alcohol Depend; 1986 Oct; 18(2):165-71. PubMed ID: 3536377
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rapid intake: a method for increasing retention rate of heroin addicts seeking methadone treatment.
    Woody G; O'Hare K; Mintz J; O'Brien C
    Compr Psychiatry; 1975; 16(2):165-9. PubMed ID: 1120417
    [No Abstract]   [Full Text] [Related]  

  • 33. Low dosage methadone treatment of narcotic dependents in Hong Kong.
    Caddow HG
    Nurs Mirror Midwives J; 1974 Jul; 139(3):66-70. PubMed ID: 4495694
    [No Abstract]   [Full Text] [Related]  

  • 34. Acute effects of methadone on EEG power spectrum and event-related potentials among heroin dependents.
    Motlagh F; Ibrahim F; Rashid R; Shafiabady N; Seghatoleslam T; Habil H
    Psychopharmacology (Berl); 2018 Nov; 235(11):3273-3288. PubMed ID: 30310960
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Methadone maintenance treatment (MMT): a review of historical and clinical issues.
    Joseph H; Stancliff S; Langrod J
    Mt Sinai J Med; 2000; 67(5-6):347-64. PubMed ID: 11064485
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Can heroin-dependent individuals benefit from a methadone maintenance treatment program before they drop out against medical advice? A 12-month follow-up study.
    Wang PW; Wu HC; Lin HC; Yen CN; Yeh YC; Chung KS; Chang HC; Yen CF
    Eur Addict Res; 2013; 19(3):155-64. PubMed ID: 23182770
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Methadone dosing, heroin affordability, and the severity of addiction.
    Bach PB; Lantos J
    Am J Public Health; 1999 May; 89(5):662-5. PubMed ID: 10224975
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population.
    Poling J; Oliveto A; Petry N; Sofuoglu M; Gonsai K; Gonzalez G; Martell B; Kosten TR
    Arch Gen Psychiatry; 2006 Feb; 63(2):219-28. PubMed ID: 16461866
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Operant analysis of human heroin self-administration and the effects of naltrexone.
    Mello NK; Mendelson JH; Kuehnle JC; Sellers MS
    J Pharmacol Exp Ther; 1981 Jan; 216(1):45-54. PubMed ID: 7452507
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Des-Gly9-[Arg8]-vasopressin may facilitate methadone detoxification of heroin addicts.
    van Beek-Verbeek G; Fraenkel HM; van Ree JM
    Subst Alcohol Actions Misuse; 1983; 4(5):375-82. PubMed ID: 6670060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.